New regimen for patients with lymphoma prolongs PFS by up to 28 months

Share This Post

12 Yue days, a study “The Lancet” published online, for CD30 -positive outer peripheral -cell lymphoma patients, this rituximab, cyclophosphamide, doxorubicin and prednisone ( A + CHP ) Better than cyclophosphamide, doxorubicin, vincristine and prednisone ( CHOP ).

Steven Horwitz , MD, from the Memorial Sloan Kettering Cancer Center in New York City and colleagues conducted a double-blind, placebo-controlled, active-control phase 3 study involving 452 patients from 132 locations in 17 countries . These patients CD30- positive peripheral T- cell lymphoma without prior treatment . Patients with 1 : 1 random allocation ratio, accepts A + CHP or of CHOP , sustained 6 , or . 8 th 21 is day cycle.

The researchers found that the median progression-free survival ( PFS ) of the A + CHP group and the CHOP group were 48.2 and 20.8 months, respectively. The incidence of side effects was similar between the two groups, including febrile neutropenia ( 18 % and 15 %, respectively) and peripheral neuropathy ( 52 % and 55 %, respectively). Fatal adverse events occurred in 3 % and 4 % of patients, respectively.

In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma patients.

Website |  + posts

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Datopotamab deruxtecan-dlnk is approved by the USFDA for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Blog

Datopotamab deruxtecan-dlnk is approved by the USFDA for unresectable or metastatic, HR-positive, HER2-negative breast cancer

The FDA has approved datopotamab deruxtecan (Dato-DXd) to treat unresectable or metastatic HR-positive, HER2-negative breast cancer following previous endocrine treatment and chemotherapy. The drug treats the disease by delivering targeted chemotherapy, enhancing the outcome for patients with advanced disease. Approval has been made based on clinical trial results demonstrating efficacy and safety. This is an important step towards providing greater treatment options for patients who have limited choices in metastatic breast cancer.

Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer
Cancer

Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer

The FDA has also approved the combination of sotorasib and panitumumab to treat KRAS G12C-mutated colorectal cancer that advanced on previous treatments. This represents a critical step forward in targeted therapy for patients with colorectal cancer having this mutation. The approval is supported by clinical trial results showing better outcomes. The combination presents a new promise to patients with few options, reaffirming the value of precision medicine in oncology.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟